CoRegen
CoRegen is a pioneering biotech company dedicated to transforming cancer treatment through groundbreaking science. Their mission is to eradicate cancer by unlocking the immune system's ability to see and destroy cancer cells, using innovative gene editing and immunotherapy technologies. With a focus on accessible outpatient therapies, they aim to make a global impact on healthcare.
Industries
biotechnology
Nr. of Employees
medium (51-250)
Products
SRC-3 knockout regulatory T cell adoptive cell therapy (autologous)
Autologous regulatory T cells isolated from patient blood, genetically edited to disrupt a transcriptional coactivator gene, processed and reinfused to promote anti-tumor immunity against solid tumors.
SRC-3 knockout regulatory T cell therapy (allogeneic)
Allogeneic regulatory T cell product concept with targeted disruption of a transcriptional coactivator gene intended for use against solid tumors.
SRC-3 knockout regulatory T cell adoptive cell therapy (autologous)
Autologous regulatory T cells isolated from patient blood, genetically edited to disrupt a transcriptional coactivator gene, processed and reinfused to promote anti-tumor immunity against solid tumors.
SRC-3 knockout regulatory T cell therapy (allogeneic)
Allogeneic regulatory T cell product concept with targeted disruption of a transcriptional coactivator gene intended for use against solid tumors.
Expertise Areas
- Cell therapy development
- Gene-editing platform development
- Treg biology and engineering
- Preclinical oncology models
Key Technologies
- CRISPR/Cas9-based gene editing (including Cas9 fusion constructs)
- Ex vivo adoptive cell transfer workflows
- In vivo antibody-directed gene editing
- Leukapheresis and cell separation